The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes

被引：6

作者：

Goyal A. ^{[1
]}

Petersen J.L. ^{[1
]}

Mahaffey K.W. ^{[1
]}

机构：

[1] Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27715

来源：

Current Cardiology Reports | 2004年 / 6卷 / 4期

关键词：

Statin; Acute Coronary Syndrome; Acute Myocardial Infarction; Atorvastatin; Pravastatin;

D O I：

10.1007/s11886-004-0080-1

中图分类号：

学科分类号：

摘要：

Dyslipidemia and hyperglycemia are common among patients presenting with acute coronary syndromes (ACS), and patients with ACS and metabolic disorders are at increased risk for worse outcomes. Although guidelines for the diagnosis and management of dyslipidemia, diabetes, and the metabolic syndrome have been published, these guidelines have not specifically focused on the ACS patient population. Recent observational registries and clinical trials have advanced the appreciation of these disorders in ACS populations and data from these studies support aggressive efforts to diagnose and treat dyslipidemia and hyperglycemia in patients admitted for ACS. Copyright © 2004 by Current Science Inc.

引用

页码：300 / 307

页数：7

共 47 条

[1] Cannon C.P., Weintraub W.S., Demopoulos L.A., Et al., Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban, N. Engl. J. Med., 344, pp. 1879-1887, (2001)
[2] Cohen M., Demers C., Gurfinkel E.P., Et al., A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease, N. Engl. J. Med., 337, pp. 447-452, (1997)
[3] Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomized multicenter study, Lancet, 354, pp. 708-715, (1999)
[4] Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol on adults (adult treatment panel III), JAMA, 285, pp. 2486-2497, (2001)
[5] Fresco C., Maggioni A.P., Signorini S., Et al., Variations in lipoprotein levels after myocardial infarction and unstable angina: The LATIN trial, Ital. Heart J., 3, pp. 587-592, (2002)
[6] Rauoof M.A., Iqbal K., Mir M.M., Tramboo N.A., Measurement of plasma lipids in patients admitted with acute myocardial infarction or unstable angina pectoris, Am. J. Cardiol., 88, pp. 165-167, (2001)
[7] Henkin Y., Crystal E., Goldberg Y., Et al., Usefulness of lipoprotein changes during acute coronary syndromes for predicting postdischarge lipoprotein levels, Am. J. Cardiol., 89, pp. 7-11, (2002)
[8] Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N. Engl. J. Med., 339, pp. 1349-1357, (1998)
[9] Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S), Lancet, 344, pp. 1383-1389, (1994)
[10] Sacks F.M., Pfeffer M.A., Moye L.A., Et al., The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N. Engl. J. Med., 335, pp. 1001-1009, (1996)

← 1 2 3 4 5 →